Tilo Schwientek

Title: Tilo Schwientek: Innovator in Glycosylated VWF Fusion Proteins

Introduction

Tilo Schwientek is a notable inventor based in Neuss, Germany. He has made significant contributions to the field of biopharmaceuticals, particularly through his innovative work on fusion proteins. His research focuses on enhancing the pharmacokinetics of therapeutic proteins, which is crucial for improving patient outcomes.

Latest Patents

Tilo Schwientek holds a patent for "Glycosylated VWF fusion proteins with improved pharmacokinetics." This invention relates to a fusion protein that includes a main protein and one or more extension peptides. The amino acid sequence of the main protein is either identical or similar to that of a mammalian protein or a fragment thereof. The extension peptide contains a cluster of O-glycosylated amino acids and is identical to a non-repeated sequence of the mammalian protein. The main protein is preferably von Willebrand factor (VWF). This fusion protein exhibits an increased half-life compared to the main protein and can be utilized to enhance the half-life of a binding partner, such as FVIII. The patent also encompasses the complex formed by the fusion protein, a polynucleotide encoding the fusion protein, as well as a vector and host cell that includes the polynucleotide.

Career Highlights

Tilo Schwientek is currently associated with Octapharma AG, a leading company in the development of human proteins for therapeutic use. His work at Octapharma has allowed him to focus on innovative solutions in the field of hemophilia and other bleeding disorders. His expertise in protein engineering has positioned him as a key figure in advancing therapeutic options for patients.

Collaborations

Tilo has collaborated with notable colleagues such as Christoph Kannicht and Barbara Solecka-Witulska. These collaborations have fostered a productive environment for research and development, leading to advancements in biopharmaceutical technologies.

Conclusion

Tilo Schwientek's contributions to the field of biopharmaceuticals, particularly through his patent on glycosylated VWF fusion proteins, highlight his innovative spirit and dedication to improving therapeutic outcomes. His work continues to influence the development of effective treatments for patients with bleeding disorders.